These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 18576909)

  • 21. Renal toxicity due to inhaled tobramycin in lung transplant recipients.
    Laporta R; Ussetti P; Carreño MC
    J Heart Lung Transplant; 2006 May; 25(5):608. PubMed ID: 16678043
    [No Abstract]   [Full Text] [Related]  

  • 22. Tobramycin for the treatment of bacterial pneumonia in children.
    Bothra M; Lodha R; Kabra SK
    Expert Opin Pharmacother; 2012 Mar; 13(4):565-71. PubMed ID: 22292783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring.
    Stenbit AE; Bullington WM; Heh JL; Flume PA
    J Cyst Fibros; 2013 Jul; 12(4):403-6. PubMed ID: 23266092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Falsely elevated serum tobramycin concentrations in cystic fibrosis patients treated with concurrent intravenous and inhaled tobramycin.
    Elidemir O; Maciejewski SR; Oermann CM
    Pediatr Pulmonol; 2000 Jan; 29(1):43-5. PubMed ID: 10613786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis: a pilot project.
    Coates AL; Green M; Leung K; Chan J; Ribeiro N; Louca E; Ratjen F; Charron M; Tservistas M; Keller M
    Pediatr Pulmonol; 2008 Aug; 43(8):753-9. PubMed ID: 18613006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nebulisers comparison with inhaled tobramycin in young children with cystic fibrosis.
    Clavel A; Boulaméry A; Bosdure E; Luc C; Lanteaume A; Gorincour G; Stremler-Lebel N; Sarles J; Andrieu V; Dubus JC
    J Cyst Fibros; 2007 Apr; 6(2):137-43. PubMed ID: 16839826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detectable Concentrations of Inhaled Tobramycin in Critically Ill Children Without Cystic Fibrosis: Should Routine Monitoring Be Recommended?
    Miller JL; Lepa TM; Ranallo C; Chaaban H; Skrepnek GH; Johnson PN
    Pediatr Crit Care Med; 2017 Dec; 18(12):e615-e620. PubMed ID: 29206744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High tobramycin serum concentrations after tobramycin inhalation in a child with renal failure.
    de Velde F; Emonts M; Verbruggen S; van der Sijs H
    J Antimicrob Chemother; 2014 Nov; 69(11):3163-4. PubMed ID: 25006239
    [No Abstract]   [Full Text] [Related]  

  • 29. Vestibulotoxicity as a consequence of systemically administered tobramycin in cystic fibrosis patients.
    Scheenstra RJ; Rijntjes E; Tavy DL; Kingma H; Heijerman HG
    Acta Otolaryngol; 2009 Jan; 129(1):4-7. PubMed ID: 18607923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.
    Coulthard KP; Peckham DG; Conway SP; Smith CA; Bell J; Turnidge J
    J Cyst Fibros; 2007 Apr; 6(2):125-30. PubMed ID: 16829216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuralgic amyotrophy associated with antibiotic therapy.
    Finstad K; Guajardo JR; Scoville C
    Ann Pharmacother; 2008 Sep; 42(9):1344-7. PubMed ID: 18682542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Administration of tobramycin in the beginning of the hemodialysis session: a novel intradialytic dosing regimen.
    Kamel Mohamed OH; Wahba IM; Watnick S; Earle SB; Bennett WM; Ayres JW; Munar MY
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):694-9. PubMed ID: 17699484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The treatment of cystic fibrosis--step by step.
    Hazinski TA
    J Pediatr; 2001 Oct; 139(4):3A. PubMed ID: 11598588
    [No Abstract]   [Full Text] [Related]  

  • 34. Monitoring of tobramycin levels in patients with cystic fibrosis by finger-prick sampling.
    Jones A; Beisty J; McKenna D; Clough D; Webb K; Morris J; Keevil B
    Eur Respir J; 2012 Jun; 39(6):1537-8. PubMed ID: 22654009
    [No Abstract]   [Full Text] [Related]  

  • 35. Acute renal failure associated with inhaled tobramycin.
    Cannella CA; Wilkinson ST
    Am J Health Syst Pharm; 2006 Oct; 63(19):1858-61. PubMed ID: 16990632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breast-feeding in a woman with cystic fibrosis undergoing antibiotic intravenous treatment.
    Festini F; Ciuti R; Taccetti G; Repetto T; Campana S; De Martino M
    J Matern Fetal Neonatal Med; 2006 Jun; 19(6):375-6. PubMed ID: 16801316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
    Tré-Hardy M; Traore H; El Manssouri N; Vanderbist F; Vaneechoutte M; Devleeschouwer MJ
    Int J Antimicrob Agents; 2009 Oct; 34(4):370-4. PubMed ID: 19505804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Suboptimal aminoglycoside dosing in critically ill patients.
    Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
    Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detectable serum tobramycin concentrations in a patient with renal dysfunction receiving tobramycin by inhalation.
    Langley A; Cottingham L
    Am J Health Syst Pharm; 2011 Aug; 68(15):1385-6. PubMed ID: 21785021
    [No Abstract]   [Full Text] [Related]  

  • 40. Serum tobramycin levels in low- and very low-birthweight infants.
    Cordero L; Arwood L; Hann C; Visconti J
    Am J Perinatol; 1984 Apr; 1(3):242-6. PubMed ID: 6525212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.